Bull case
AME would need investors to value it at roughly 46x earnings — about 17x more generous than today's 29x forward P/E. That requires meaningful multiple expansion on top of continued earnings growth.
Wall Street verdict, consensus price target, and analyst rating breakdown — everything needed to frame the risk/reward at today's price.
Three scenarios for where AME stock could go
AME would need investors to value it at roughly 46x earnings — about 17x more generous than today's 29x forward P/E. That requires meaningful multiple expansion on top of continued earnings growth.
At 35x on FY1 earnings, the base case reflects a reasonable but not stretched valuation. It prices in continued growth without assuming an exceptional setup.
If investor confidence fades or macro conditions deteriorate, a 7x multiple contraction could push AME down roughly 25% from where it trades now.
Not financial advice. Model confidence reflects internal scenario assumptions, not a guarantee of returns. Past performance does not predict future results.

AMETEK is a diversified manufacturer of precision electronic instruments and electromechanical devices for industrial, aerospace, and power markets. It generates revenue primarily through its Electronic Instruments segment (~70% of sales) and Electromechanical segment (~30%), selling highly engineered components and systems. The company's competitive advantage lies in its deep domain expertise across niche industrial applications and a disciplined acquisition strategy that builds a portfolio of market-leading, high-margin businesses.
Quarterly beat-or-miss track record against analyst estimates, plus forward revenue and EPS outlook for the next two fiscal years.
| Quarter | EPS (Actual / Est) | EPS Surprise | Revenue (Actual / Est) | Rev Surprise |
|---|---|---|---|---|
| Q3 2025 | $1.78/$1.69 | +5.3% | $1.8B/$1.7B | +2.5% |
| Q4 2025 | $1.89/$1.76 | +7.4% | $1.9B/$1.8B | +4.3% |
| Q1 2026 | $2.01/$1.94 | +3.6% | $2.0B/$1.9B | +2.7% |
| Q2 2026 | $1.97/$1.90 | +3.7% | $1.9B/$1.9B | +0.7% |
AME beat EPS estimates in 4 of 4 tracked quarters. A perfect track record raises the bar for the upcoming report.
Product and geographic revenue mix from the latest annual disclosure, with year-over-year growth by segment.
Latest annual revenue by segment or product family
Tap, hover, or focus a slice to inspect segment detail.
Latest annual revenue by reported region
Tap, hover, or focus a slice to inspect segment detail.
Current multiples compared to the S&P 500, the company's sector, and its own five-year average.
Fair value est. $176 — implies -25.7% from today's price.
| Metric | AME | S&P 500 | Industrials | 5Y Avg AME |
|---|---|---|---|---|
| Forward PE | 29.2x | 18.8x+55% | 21.2x+38% | — |
| Trailing PE | 37.1x | 24.4x+52% | 25.6x+45% | 30.8x+20% |
| PEG Ratio | 3.32x | 1.66x+100% | 1.65x+102% | — |
| EV/EBITDA | 29.9x | 15.2x+97% | 13.9x+115% | 21.7x+38% |
| Price/FCF | 32.5x | 20.7x+57% | 20.0x+62% | 28.3x+15% |
| Price/Sales | 7.3x | 3.1x+138% | 1.6x+370% | 5.9x+24% |
| Dividend Yield | 0.52% | 1.91% | 1.21% | 0.60% |
Forward P/E and PEG reflect analyst consensus estimates. Historical averages use trailing ratios where forward data is unavailable.S&P 500 and sector benchmarks both use trailing median P/E — similar readings indicate the broader index and sector are priced alike.
Open valuation toolAME generates $1.7B in free cash flow at a 22.4% margin — 12.1% ROIC signals a durable competitive advantage · returns 1.3% of market cap to shareholders annually.
Revenue, margins, and cash generation
ROIC, leverage, and debt serviceability
~1.1 years to full repayment at current FCF run-rate
How capital is returned to owners
All figures from the trailing twelve months. ROIC uses invested capital (equity + net debt).
Open full ratios pageKey factors that could pressure the stock price, compress the multiple, or weigh on future results.
AI analysis · updated June 17, 2026
AMETEK's outlook is shaped by tariff uncertainty as it enters 2026, potentially impacting its financial performance.
The acquisition of LKC Technologies increases healthcare exposure but carries integration risks and potential execution challenges.
AI models and analyst targets suggest limited upside potential for AME stock, with some forecasts showing minimal growth.
AMETEK serves niche markets, and any downturn in key sectors like energy or aerospace could negatively impact revenue.
With consensus targets implying modest upside, there may be valuation concerns if growth fails to meet expectations.
These are risk mechanisms, not predictions. The key question is which would force a cut to earnings estimates or a lower multiple than the market currently prices in.
Structural drivers behind the upside case and why the stock could outperform over the next 12 months.
AI analysis · updated June 17, 2026
AMETEK reported a record backlog of $3.58 billion, driven by 18% total order growth and 7% organic order growth, providing strong revenue visibility into 2026.
Recent innovations now account for about one-third of AMETEK's revenue growth, highlighting the company's ability to drive top-line expansion through new products.
The company issued mid-to-high single-digit sales growth guidance for 2026 and reported record Q4 and full-year 2025 results, signaling continued momentum.
AMETEK approved a 10% increase in its quarterly cash dividend to $0.34 per share, demonstrating confidence in its financial position and commitment to shareholder returns.
As a global leader in electronic instruments and electromechanical devices, AMETEK serves attractive niche markets across energy, aerospace, medical, and industrial sectors.
The bull case assumes continued margin expansion, supported by resilient aerospace and semiconductor orders, which could drive earnings growth.
Wall Street projects $7.98 billion in 2026 revenue (up 7.8% YoY), supported by strong backlog and order growth, aligning with bullish expectations.
A real bull case compounds — each driver matters most when it strengthens margins, supports capital returns, and keeps the company above the market's minimum growth bar simultaneously.
52-week range context and price returns across multiple time horizons. Dividend contribution is shown separately in the Capital Return section.
Range context matters because valuation compression and earnings misses rarely hit from the same starting point. A stock already far below its high can still fall, but it is no longer carrying the same embedded optimism as one pressing a fresh peak.
Valuation, growth, and margin comparison against the closest publicly traded peers for this company.
| Company | Mkt Cap | Fwd PE | Rev Grw | Margin | Rating | Upside |
|---|---|---|---|---|---|---|
AME AME AMETEK, Inc. | $54.4B | 29.2x | +6.6% | 20.1% | Buy | +5.3% |
DHR DHR Danaher Corporation | $125.4B | 21.0x | +3.5% | 14.9% | Buy | +30.3% |
ROP ROP Roper Technologies, Inc. | $34.0B | 15.1x | +8.1% | 21.1% | Buy | +38.6% |
FTV FTV Fortive Corporation | $18.8B | 20.4x | 0.0% | 11.5% | Hold | +1.6% |
ITW ITW Illinois Tool Works Inc. | $76.1B | 23.4x | +2.8% | 19.3% | Hold | +2.7% |
PNR PNR Pentair plc | $12.0B | 13.9x | +2.6% | 16.0% | Hold | +44.6% |
This peer comparison reflects companies with similar business models, product lines, or market positioning, supplemented by industry grouping when direct matches are limited.
AME returns capital mainly through $434M/year in buybacks (0.8% buyback yield), with a modest 0.52% dividend — combining for 1.3% total shareholder yield. The dividend has grown for 6 consecutive years.
Yield, cadence, and growth quality
How much per-share support comes from repurchases
| Year | Div / Share | YoY Grw | BB Yield | Total Yield |
|---|---|---|---|---|
| 2026 | $0.68 | — | — | — |
| 2025 | $1.24 | +10.7% | 0.9% | 1.5% |
| 2024 | $1.12 | +12.0% | 0.5% | 1.1% |
| 2023 | $1.00 | +13.6% | 0.0% | 0.6% |
| 2022 | $0.88 | +10.0% | 1.0% | 1.7% |
Common questions answered from live analyst data and company financials.
AMETEK, Inc. (AME) is rated Buy by Wall Street analysts as of 2026. Of 29 analysts covering the stock, 20 rate it Buy or Strong Buy, 9 rate it Hold, and 0 rate it Sell or Strong Sell. The consensus 12-month price target is $250, implying +5.3% from the current price of $237. The bear case scenario is $179 and the bull case is $374.
The Wall Street consensus price target for AME is $250 based on 29 analyst estimates. The high-end target is $275 (+15.8% from today), and the low-end target is $215 (-9.4%). The base case model target is $284.
AME trades at 29.2x times forward earnings. The stock trades at a notable premium to the broad market, which is typical for businesses with strong free cash flow and above-average growth expectations. Based on current multiples versus the peer group, the relative model signals expensive versus peers. Whether the stock is over or undervalued ultimately depends on whether consensus earnings estimates are achievable.
The primary risks for AME in 2026 are: (1) Tariff uncertainty — AMETEK's outlook is shaped by tariff uncertainty as it enters 2026, potentially impacting its financial performance. (2) Acquisition integration risk — The acquisition of LKC Technologies increases healthcare exposure but carries integration risks and potential execution challenges. (3) Market concentration risk — AMETEK serves niche markets, and any downturn in key sectors like energy or aerospace could negatively impact revenue. Each factor has the potential to pressure earnings or compress the stock's valuation multiple.
Analyst consensus estimates AME will report consensus revenue of $8.1B (+6.6% year-over-year) and EPS of $7.49 (+12.6% year-over-year) for the upcoming fiscal year. The following year, analysts project $8.6B in revenue.
AMETEK, Inc. is expected to report its next earnings on approximately 2026-07-30. Consensus expects EPS of $1.99 and revenue of $2.0B. Over recent quarters, AME has beaten EPS estimates 100% of the time.
AMETEK, Inc. (AME) generated $1.7B in free cash flow over the trailing twelve months — a free cash flow margin of 22.4%. AME returns capital to shareholders through dividends (0.5% yield) and share repurchases ($434M TTM).